{"news_desk": "Letters", "print_page": "26", "subsection_name": null, "section_name": "Opinion", "byline": [], "abstract": null, "type_of_material": "Letter", "word_count": "194", "keywords": [{"rank": "1", "value": "Clinical Trials", "is_major": "N", "name": "subject"}, {"rank": "2", "value": "Food and Drug Administration", "is_major": "N", "name": "organizations"}, {"rank": "3", "value": "Minorities", "is_major": "N", "name": "subject"}], "lead_paragraph": "Officials of the Food and Drug Administration discuss steps the agency is taking to increase diversity in drug trials.", "pub_date": "2017-01-18T19:58:42+0000", "document_type": "article", "source": "The New York Times", "snippet": "Officials of the Food and Drug Administration discuss steps the agency is taking to increase diversity in drug trials....", "multimedia": [], "web_url": "http://www.nytimes.com/2017/01/18/opinion/diversity-in-clinical-trials.html", "slideshow_credits": null, "blog": [], "_id": "587fc8fa95d0e0392607b6f7", "headline": {"main": "Diversity in Clinical Trials", "content_kicker": "Letter", "print_headline": "Diversity in Clinical Trials", "kicker": "Letter"}}